{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,3]],"date-time":"2026-07-03T23:18:30Z","timestamp":1783120710540,"version":"3.54.6"},"reference-count":27,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,3,18]],"date-time":"2026-03-18T00:00:00Z","timestamp":1773792000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100003196","name":"Ministry of Health","doi-asserted-by":"publisher","award":["GR-2016-02361134"],"award-info":[{"award-number":["GR-2016-02361134"]}],"id":[{"id":"10.13039\/501100003196","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000780","name":"European Commission","doi-asserted-by":"publisher","award":["CUP B33C22001030006"],"award-info":[{"award-number":["CUP B33C22001030006"]}],"id":[{"id":"10.13039\/501100000780","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100005010","name":"Italian Association for Cancer Research","doi-asserted-by":"publisher","award":["30711"],"award-info":[{"award-number":["30711"]}],"id":[{"id":"10.13039\/501100005010","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100024370","name":"Ministero dell'Istruzione dell'Universit\u00e0 e della Ricerca","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100024370","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100021856","name":"Ministero dell'Universit\u00e0 e della Ricerca","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100021856","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","esmoopen.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["ESMO Open"],"published-print":{"date-parts":[[2026,5]]},"DOI":"10.1016\/j.esmoop.2026.106964","type":"journal-article","created":{"date-parts":[[2026,5,5]],"date-time":"2026-05-05T17:44:46Z","timestamp":1778003086000},"page":"106964","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Perioperative NALIRIFOX in patients with resectable pancreatic ductal adenocarcinoma: updated analysis of survival and circulating and genetic biomarkers from the phase II nITRO trial"],"prefix":"10.1016","volume":"11","author":[{"ORCID":"https:\/\/orcid.org\/0009-0009-3263-9830","authenticated-orcid":false,"given":"E.","family":"Scarlato","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2120-1923","authenticated-orcid":false,"given":"V.","family":"Merz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Pietrobono","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0895-6387","authenticated-orcid":false,"given":"S.","family":"Casalino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2142-1352","authenticated-orcid":false,"given":"A.","family":"Quinzii","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Zecchetto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0009-1041-151X","authenticated-orcid":false,"given":"L.","family":"Mendo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Giacomazzi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Bonato","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0001-2606-2977","authenticated-orcid":false,"given":"V.","family":"De Vita","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9172-4885","authenticated-orcid":false,"given":"G.","family":"Butturini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3514-8473","authenticated-orcid":false,"given":"R.","family":"Salvia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4031-7585","authenticated-orcid":false,"given":"D.","family":"Melisi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"4","key":"10.1016\/j.esmoop.2026.106964_bib1","doi-asserted-by":"crossref","first-page":"439","DOI":"10.6004\/jnccn.2021.0017","article-title":"Pancreatic adenocarcinoma, version 2.2021, NCCN clinical practice guidelines in oncology","volume":"19","author":"Tempero","year":"2021","journal-title":"J Natl Compr Canc Netw"},{"issue":"11","key":"10.1016\/j.esmoop.2026.106964_bib2","doi-asserted-by":"crossref","first-page":"1571","DOI":"10.1001\/jamaoncol.2022.3829","article-title":"Five-year outcomes of FOLFIRINOX vs gemcitabine as adjuvant therapy for pancreatic cancer: a randomized clinical trial","volume":"8","author":"Conroy","year":"2022","journal-title":"JAMA Oncol"},{"issue":"10","key":"10.1016\/j.esmoop.2026.106964_bib3","doi-asserted-by":"crossref","first-page":"1139","DOI":"10.1001\/jamasurg.2024.2485","article-title":"Futility of up-front resection for anatomically resectable pancreatic cancer","volume":"159","author":"Crippa","year":"2024","journal-title":"JAMA Surg"},{"issue":"12","key":"10.1016\/j.esmoop.2026.106964_bib4","doi-asserted-by":"crossref","first-page":"4108","DOI":"10.1245\/s10434-019-07602-6","article-title":"Completion of adjuvant chemotherapy after upfront surgical resection for pancreatic cancer is uncommon yet associated with improved survival","volume":"26","author":"Altman","year":"2019","journal-title":"Ann Surg Oncol"},{"issue":"2","key":"10.1016\/j.esmoop.2026.106964_bib5","doi-asserted-by":"crossref","DOI":"10.1093\/bjsopen\/zrac010","article-title":"Prognostic relevance of the revised R status definition in pancreatic cancer: meta-analysis","volume":"6","author":"Leonhardt","year":"2022","journal-title":"BJS Open"},{"issue":"7","key":"10.1016\/j.esmoop.2026.106964_bib6","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1001\/jamasurg.2021.0149","article-title":"Clinical trials of systemic chemotherapy for resectable pancreatic cancer: a review","volume":"156","author":"Mavros","year":"2021","journal-title":"JAMA Surg"},{"issue":"5","key":"10.1016\/j.esmoop.2026.106964_bib7","doi-asserted-by":"crossref","first-page":"1223","DOI":"10.4240\/wjgs.v16.i5.1223","article-title":"Neoadjuvant treatment of pancreatic ductal adenocarcinoma: whom, when and how","volume":"16","author":"Manojlovic","year":"2024","journal-title":"World J Gastrointest Surg"},{"issue":"suppl","key":"10.1016\/j.esmoop.2026.106964_bib8","article-title":"NAPOLI-3: a randomized, open-label phase 3 study of liposomal irinotecan + 5-fluorouracil\/leucovorin + oxaliplatin (NALIRIFOX) versus nab-paclitaxel + gemcitabine in treatment-na\u00efve patients with metastatic pancreatic ductal adenocarcinoma (mPDAC)","volume":"41","author":"Wainberg","year":"2023","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.esmoop.2026.106964_bib9","doi-asserted-by":"crossref","DOI":"10.1177\/17588359241234487","article-title":"Integration of liposomal irinotecan in the first-line treatment of metastatic pancreatic cancer: try to do not think about the white bear","volume":"16","author":"Melisi","year":"2024","journal-title":"Ther Adv Med Oncol"},{"issue":"8","key":"10.1016\/j.esmoop.2026.106964_bib10","doi-asserted-by":"crossref","DOI":"10.1016\/j.esmoop.2025.105534","article-title":"Health-related quality of life and performance status with NALIRIFOX versus nab-paclitaxel + gemcitabine in treatment-naive patients with metastatic pancreatic ductal adenocarcinoma: results from the NAPOLI 3 trial","volume":"10","author":"Melisi","year":"2025","journal-title":"ESMO Open"},{"issue":"7","key":"10.1016\/j.esmoop.2026.106964_bib11","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1080\/14796694.2025.2458458","article-title":"A plain language summary of NALIRIFOX compared with nab-paclitaxel and gemcitabine for patients with metastatic pancreatic cancer (NAPOLI 3)","volume":"21","author":"Wainberg","year":"2025","journal-title":"Future Oncol"},{"key":"10.1016\/j.esmoop.2026.106964_bib12","doi-asserted-by":"crossref","DOI":"10.1177\/1758835920947969","article-title":"A phase II study of liposomal irinotecan with 5-fluorouracil, leucovorin and oxaliplatin in patients with resectable pancreatic cancer: the nITRO trial","volume":"12","author":"Simionato","year":"2020","journal-title":"Ther Adv Med Oncol"},{"key":"10.1016\/j.esmoop.2026.106964_bib13","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejca.2023.113430","article-title":"Perioperative NALIRIFOX in patients with resectable pancreatic ductal adenocarcinoma: the open-label, multicenter, phase II nITRO trial","volume":"196","author":"Melisi","year":"2024","journal-title":"Eur J Cancer"},{"issue":"3","key":"10.1016\/j.esmoop.2026.106964_bib14","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1038\/s41416-019-0582-7","article-title":"Platinum response characteristics of patients with pancreatic ductal adenocarcinoma and a germline BRCA1, BRCA2 or PALB2 mutation","volume":"122","author":"Wattenberg","year":"2020","journal-title":"Br J Cancer"},{"issue":"2","key":"10.1016\/j.esmoop.2026.106964_bib15","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1200\/PO.17.00152","article-title":"Retrospective survival analysis of patients with advanced pancreatic ductal adenocarcinoma and germline BRCA or PALB2 mutations","volume":"2","author":"Reiss","year":"2018","journal-title":"JCO Precis Oncol"},{"key":"10.1016\/j.esmoop.2026.106964_bib16","doi-asserted-by":"crossref","DOI":"10.1016\/j.canlet.2025.217699","article-title":"Tumor immune microenvironment in pancreatic ductal adenocarcinoma revisited\u2014exploring the \u201cSpace\u201d","volume":"622","author":"Br\u00e4utigam","year":"2025","journal-title":"Cancer Lett"},{"key":"10.1016\/j.esmoop.2026.106964_bib17","doi-asserted-by":"crossref","DOI":"10.3389\/fcell.2021.727075","article-title":"Tumor necrosis factor alpha signaling and organogenesis","volume":"9","author":"You","year":"2021","journal-title":"Front Cell Dev Biol"},{"key":"10.1016\/j.esmoop.2026.106964_bib18","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1016\/j.drup.2017.10.004","article-title":"TAK-ing aim at chemoresistance: the emerging role of MAP3K7 as a target for cancer therapy","volume":"33-35","author":"Santoro","year":"2017","journal-title":"Drug Resist Updat"},{"issue":"6","key":"10.1016\/j.esmoop.2026.106964_bib19","doi-asserted-by":"crossref","first-page":"878","DOI":"10.1038\/bjc.2015.283","article-title":"TAK1-regulated expression of BIRC3 predicts resistance to preoperative chemoradiotherapy in oesophageal adenocarcinoma patients","volume":"113","author":"Piro","year":"2015","journal-title":"Br J Cancer"},{"issue":"17","key":"10.1016\/j.esmoop.2026.106964_bib20","doi-asserted-by":"crossref","first-page":"4661","DOI":"10.1158\/1078-0432.CCR-20-0395","article-title":"Plasma IL8 is a biomarker for TAK1 activation and predicts resistance to nanoliposomal irinotecan in patients with gemcitabine-refractory pancreatic cancer","volume":"26","author":"Merz","year":"2020","journal-title":"Clin Cancer Res"},{"issue":"15","key":"10.1016\/j.esmoop.2026.106964_bib21","doi-asserted-by":"crossref","first-page":"1190","DOI":"10.1093\/jnci\/djr243","article-title":"Modulation of pancreatic cancer chemoresistance by inhibition of TAK1","volume":"103","author":"Melisi","year":"2011","journal-title":"J Natl Cancer Inst"},{"issue":"3","key":"10.1016\/j.esmoop.2026.106964_bib22","doi-asserted-by":"crossref","first-page":"1151","DOI":"10.1016\/j.jcmgh.2021.06.005","article-title":"A novel atTAK against hepatocellular carcinoma: overcoming resistance to sorafenib","volume":"12","author":"Pietrobono","year":"2021","journal-title":"Cell Mol Gastroenterol Hepatol"},{"issue":"1","key":"10.1016\/j.esmoop.2026.106964_bib23","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1158\/1535-7163.MCT-19-0270","article-title":"Modulating TAK1 expression inhibits YAP and TAZ oncogenic functions in pancreatic cancer","volume":"19","author":"Santoro","year":"2020","journal-title":"Mol Cancer Ther"},{"issue":"1","key":"10.1016\/j.esmoop.2026.106964_bib24","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1038\/s41698-024-00742-3","article-title":"CCL3 predicts exceptional response to TGF\u03b2 inhibition in basal-like pancreatic cancer enriched in LIF-producing macrophages","volume":"8","author":"Pietrobono","year":"2024","journal-title":"NPJ Precis Oncol"},{"issue":"6","key":"10.1016\/j.esmoop.2026.106964_bib25","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1038\/bjc.2017.19","article-title":"Overall survival and clinical characteristics of BRCA mutation carriers with stage I\/II pancreatic cancer","volume":"116","author":"Golan","year":"2017","journal-title":"Br J Cancer"},{"issue":"10","key":"10.1016\/j.esmoop.2026.106964_bib26","doi-asserted-by":"crossref","first-page":"3963","DOI":"10.1245\/s10434-020-08469-8","article-title":"Increased rate of complete pathologic response after neoadjuvant FOLFIRINOX for BRCA mutation carriers with borderline resectable pancreatic cancer","volume":"27","author":"Golan","year":"2020","journal-title":"Ann Surg Oncol"},{"issue":"5","key":"10.1016\/j.esmoop.2026.106964_bib27","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1038\/gim.2015.30","article-title":"Standards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology","volume":"17","author":"Richards","year":"2015","journal-title":"Genet Med"}],"container-title":["ESMO Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2059702926009063?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2059702926009063?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,7,3]],"date-time":"2026-07-03T22:34:45Z","timestamp":1783118085000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2059702926009063"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5]]},"references-count":27,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2026,5]]}},"alternative-id":["S2059702926009063"],"URL":"https:\/\/doi.org\/10.1016\/j.esmoop.2026.106964","relation":{},"ISSN":["2059-7029"],"issn-type":[{"value":"2059-7029","type":"print"}],"subject":[],"published":{"date-parts":[[2026,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Perioperative NALIRIFOX in patients with resectable pancreatic ductal adenocarcinoma: updated analysis of survival and circulating and genetic biomarkers from the phase II nITRO trial","name":"articletitle","label":"Article Title"},{"value":"ESMO Open","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.esmoop.2026.106964","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier Ltd on behalf of European Society for Medical Oncology.","name":"copyright","label":"Copyright"}],"article-number":"106964"}}